Syntis Bio
Syntis Bio is a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases by unlocking the full therapeutic potential of the small intestine. The company develops innovative oral therapies leveraging the small intestine’s biology to provide accessible, effective, and sustainable healthcare solutions across a broad spectrum of conditions. Their pipeline includes programs like SYNT-101 for obesity and enzyme therapies for rare pediatric metabolic disorders, utilizing proprietary SYNT™ technology to deliver targeted, transient coatings within the gastrointestinal tract.
Industries
Nr. of Employees
small (1-50)
Syntis Bio
135 Morrissey Boulevard Ste 101A, Boston, MA 02125
Patents
Products
Once-daily oral duodenal nutrient-exclusion therapy (lead candidate, early human studies)
An oral formulation designed to transiently block nutrient absorption in the duodenum to redirect nutrients to distal small intestine regions and elicit endogenous satiety and metabolic hormone responses; being evaluated in first-in-human studies.
Oral gut-restricted enzyme therapies for orphan metabolic diseases (pre-IND / IND-enabling)
Engineered GI-stable enzyme replacement candidates designed for oral administration to degrade or control specific dietary amino acids/metabolites in the small intestine, advanced toward IND-enabling studies.
Synthetic tissue-lining platform for GI targeting
Technology platform that forms a transient polymer lining on targeted GI tissues to achieve effects including nutrient exclusion, enzyme installation, and oral bioavailability enhancement.
Once-daily oral duodenal nutrient-exclusion therapy (lead candidate, early human studies)
An oral formulation designed to transiently block nutrient absorption in the duodenum to redirect nutrients to distal small intestine regions and elicit endogenous satiety and metabolic hormone responses; being evaluated in first-in-human studies.
Oral gut-restricted enzyme therapies for orphan metabolic diseases (pre-IND / IND-enabling)
Engineered GI-stable enzyme replacement candidates designed for oral administration to degrade or control specific dietary amino acids/metabolites in the small intestine, advanced toward IND-enabling studies.
Synthetic tissue-lining platform for GI targeting
Technology platform that forms a transient polymer lining on targeted GI tissues to achieve effects including nutrient exclusion, enzyme installation, and oral bioavailability enhancement.
Services
Partnerships and co-development arrangements to apply GI-targeted polymer lining technology to improve oral absorption or sustain local GI activity of drug candidates.
Partnerships and co-development arrangements to apply GI-targeted polymer lining technology to improve oral absorption or sustain local GI activity of drug candidates.
Expertise Areas
- Oral drug delivery and formulation
- GI-targeted biomaterials
- Protein/enzyme engineering for GI stability
- Preclinical translational studies (rodent and large-animal models)
Key Technologies
- Mussel-inspired polymer chemistry
- Polydopamine-based in situ coatings
- In situ-forming GI tissue linings
- Gut-restricted enzyme formulations